These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
115 related items for PubMed ID: 15795326
1. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Steffel J, Hermann M, Greutert H, Gay S, Lüscher TF, Ruschitzka F, Tanner FC. Circulation; 2005 Apr 05; 111(13):1685-9. PubMed ID: 15795326 [Abstract] [Full Text] [Related]
2. Differential effect of celecoxib on tissue factor expression in human endothelial and vascular smooth muscle cells. Steffel J, Akhmedov A, Fähndrich C, Ruschitzka F, Lüscher TF, Tanner FC. Biochem Biophys Res Commun; 2006 Oct 20; 349(2):597-603. PubMed ID: 16949034 [Abstract] [Full Text] [Related]
3. Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Stähli BE, Camici GG, Steffel J, Akhmedov A, Shojaati K, Graber M, Lüscher TF, Tanner FC. Circ Res; 2006 Jul 21; 99(2):149-55. PubMed ID: 16794185 [Abstract] [Full Text] [Related]
5. Induction of tissue factor expression in human monocytic cells by protease inhibitors through activating activator protein-1 (AP-1) with phosphorylation of Jun-N-terminal kinase and p38. Ohsawa M, Koyama T, Nara N, Hirosawa S. Thromb Res; 2003 Jul 19; 112(5-6):313-20. PubMed ID: 15041276 [Abstract] [Full Text] [Related]
6. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Steffel J, Latini RA, Akhmedov A, Zimmermann D, Zimmerling P, Lüscher TF, Tanner FC. Circulation; 2005 Sep 27; 112(13):2002-11. PubMed ID: 16172265 [Abstract] [Full Text] [Related]
7. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Niederberger E, Manderscheid C, Grösch S, Schmidt H, Ehnert C, Geisslinger G. Biochem Pharmacol; 2004 Jul 15; 68(2):341-50. PubMed ID: 15194006 [Abstract] [Full Text] [Related]
8. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Hermann M, Camici G, Fratton A, Hurlimann D, Tanner FC, Hellermann JP, Fiedler M, Thiery J, Neidhart M, Gay RE, Gay S, Lüscher TF, Ruschitzka F. Circulation; 2003 Nov 11; 108(19):2308-11. PubMed ID: 14597594 [Abstract] [Full Text] [Related]
9. Cardiac glycosides regulate endothelial tissue factor expression in culture. Stähli BE, Breitenstein A, Akhmedov A, Camici GG, Shojaati K, Bogdanov N, Steffel J, Ringli D, Lüscher TF, Tanner FC. Arterioscler Thromb Vasc Biol; 2007 Dec 11; 27(12):2769-76. PubMed ID: 18029910 [Abstract] [Full Text] [Related]
10. Laminin receptor activation inhibits endothelial tissue factor expression. Holy EW, Stämpfli SF, Akhmedov A, Holm N, Camici GG, Lüscher TF, Tanner FC. J Mol Cell Cardiol; 2010 Jun 11; 48(6):1138-45. PubMed ID: 19712679 [Abstract] [Full Text] [Related]
11. Transcriptional regulation of VCAM-1 expression by tumor necrosis factor-alpha in human tracheal smooth muscle cells: involvement of MAPKs, NF-kappaB, p300, and histone acetylation. Lee CW, Lin WN, Lin CC, Luo SF, Wang JS, Pouyssegur J, Yang CM. J Cell Physiol; 2006 Apr 11; 207(1):174-86. PubMed ID: 16288471 [Abstract] [Full Text] [Related]
12. Berberine, a natural lipid-lowering drug, exerts prothrombotic effects on vascular cells. Holy EW, Akhmedov A, Lüscher TF, Tanner FC. J Mol Cell Cardiol; 2009 Feb 11; 46(2):234-40. PubMed ID: 19014947 [Abstract] [Full Text] [Related]
13. Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents. Camici GG, Steffel J, Akhmedov A, Schafer N, Baldinger J, Schulz U, Shojaati K, Matter CM, Yang Z, Lüscher TF, Tanner FC. Circulation; 2006 Oct 03; 114(14):1512-21. PubMed ID: 17000906 [Abstract] [Full Text] [Related]
15. Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. Klein T, Eltze M, Grebe T, Hatzelmann A, Kömhoff M. Cardiovasc Res; 2007 Jul 15; 75(2):390-7. PubMed ID: 17383621 [Abstract] [Full Text] [Related]
16. (--)-epigallocatechin gallate enhances prostaglandin F2alpha-induced VEGF synthesis via upregulating SAPK/JNK activation in osteoblasts. Tokuda H, Takai S, Matsushima-Nishiwaki R, Akamatsu S, Hanai Y, Hosoi T, Harada A, Ohta T, Kozawa O. J Cell Biochem; 2007 Apr 01; 100(5):1146-53. PubMed ID: 17031857 [Abstract] [Full Text] [Related]
17. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells. Kim YS, Ahn Y, Hong MH, Kim KH, Park HW, Hong YJ, Kim JH, Kim W, Jeong MH, Cho JG, Park JC, Kang JC. J Cardiovasc Pharmacol; 2007 Jun 01; 49(6):376-83. PubMed ID: 17577102 [Abstract] [Full Text] [Related]
18. Guggulsterone, an anti-inflammatory phytosterol, inhibits tissue factor and arterial thrombosis. Gebhard C, Stämpfli SF, Gebhard CE, Akhmedov A, Breitenstein A, Camici GG, Holy EW, Lüscher TF, Tanner FC. Basic Res Cardiol; 2009 May 01; 104(3):285-94. PubMed ID: 18953480 [Abstract] [Full Text] [Related]
19. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. Kwak HJ, Song JS, Heo JY, Yang SD, Nam JY, Cheon HG. J Pharmacol Exp Ther; 2005 Dec 01; 315(3):1188-95. PubMed ID: 16126838 [Abstract] [Full Text] [Related]
20. IL-1 and TNF induction of matrix metalloproteinase-3 by c-Jun N-terminal kinase in trabecular meshwork. Hosseini M, Rose AY, Song K, Bohan C, Alexander JP, Kelley MJ, Acott TS. Invest Ophthalmol Vis Sci; 2006 Apr 01; 47(4):1469-76. PubMed ID: 16565381 [Abstract] [Full Text] [Related] Page: [Next] [New Search]